Release date: February 25, 2022

Expiration date: February 25, 2023

Estimated time to complete medical and pharmacy track: 9.0 hours

Estimated time to complete nursing track: 12.25 hours

Estimated time to complete social work track: 11 hours

Postgraduate Institute for MedicineNational Hemophilia Foundation

Jointly provided by Postgraduate Institute for Medicine and the National Hemophilia Foundation.


This enduring activity is supported by independent educational grants from Bayer HealthCare Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Novo Nordisk, Spark Therapeutics, Inc., and Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for physicians, pharmacists, researchers, physician assistants, nurse practitioners, registered nurses, and social workers who are engaged in the care of patients with bleeding disorders.

Educational Objectives and Faculty

The educational objectives for this web activity can be found on each of the Medical, Nursing and Social Work track subpages. A complete list of sessions along with faculty are available by clicking the links at the bottom of this page.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Hemophilia Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this enduring activity for 9.0 contact hours (0.9 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008162-9999-22-038-H04-P
Type of Activity: Knowledge



Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 12.25 contact hours. Designated for 4.25 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses (APRN).



Social Work Continuing Education
As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Postgraduate Institute for Medicine maintains responsibility for this course. Social workers completing this course can receive 3.0 Cultural Competency and 8.0 Clinical continuing education credits.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


To review all faculty disclosures, click here.


Planners and Managers
The PIM planners and managers have nothing to disclose. The NHF staff planners have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for these tracks. During the period February 25, 2022 through February 25, 2023, participants must read the learning objectives and faculty disclosures and study the educational activities.

If you wish to receive acknowledgment for completing these tracks, please complete the corresponding evaluation for your specific provider discipline by following the instructions below.

*Please complete the online evaluation(s) only after you have participated in all the sessions within each track. You will be unable to receive partial credit. You will also not be able to access the evaluation again for each track once submitted.

  1. Go to
  2. Register as a First Time User or Login (will take less than 1 minute)
    1. If you receive a message when creating a new account that “the email you entered is already in use”, please click the Forgot my Username or Password link to have your Username and Password sent to you via email
    2. After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
  3. Type in 16563 at the top of the page under "Find Post-Test/Evaluation by Course", click enter
  4. Click on the activity title/track when it appears
  5. Select the type of credit you desire
  6. Complete online Evaluation
  7. Receive an immediate CME/CE Certificate to download and/or print for your files

For Pharmacists: You must provide your NABP ePID and Date of Birth during registration on

Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

If you have questions regarding the certification of this activity, please contact PIM via email at


Computer System Requirements

  • Microsoft Windows 10 or 11; Windows Server 2008 (requires the Desktop Experience), Windows 8, Windows 7, Windows Vista
  • Browsers - Microsoft Edge, Microsoft Internet Explorer 11.0, Mozilla Firefox, or Google Chrome;
  • Broadband Internet connection
  • Note: Enterprise Video Platform 7.0.25 or EX Server 6.1.23 are required for Windows 10 support

Note: Enterprise Video Platform 7.0.25 or EX Server 6.1.23 are required for Windows 10 support

  • Apple MacOS Mac OS X 10.5.7 or later
  • Mojave (version 10.14) and higher; Apple Safari, Mozilla Firefox, or Google Chrome; Broadband Internet connection
  • Apple iPadOS 13 and higher; Apple Mobile Safari; Broadband Internet connection
  • Apple iOS 12 and higher

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


Access NHF’s BDC web activity: